-+ 0.00%
-+ 0.00%
-+ 0.00%

ADAGENE ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF ADG138, A NOVEL HER2XCD3 DOUBLE-MASKED BISPECIFIC T-CELL ENGAGER

路透·11/19/2026 12:00:02

请登录查看新闻详情